A valid biomarker of PD disease progression, plasma NfL levels are significantly increased in PD patients with advanced disease and dementia, demonstrating that NfL levels correlate with disease severity as well as motor and cognitive function in PD patients (Lin et al., 2019). The gene discussed is NEFL; the disease is Parkinson disease.